Skip to main content

Table 4 Characteristics of quality of life values used

From: Cost-effectiveness of prostate cancer screening: a systematic review of decision-analytical models

Study Study setting Perspective Assessment of QoL Population Country
Chilcott et al. [23] UK NHS HUI/EQ-5D General population UK/other
Heijnsdijk et al. [25] NR Healthcare based on included costs SG/EQ-5D/TTO/VAS Patients/experts/ general population Netherlands, US, Canada
Hummel and Chilcott [24] UK NHS HUI/EQ-5D General population UK/other
Keller et al. [29] Australia Healthcare SF-12/ SF-36/ othera, b General population Australia/ Finland
Kobayashi et al. [27] NR Societal TTO Physicians/ patients Unclear
Martin et al. [30] Australia Healthcare SF-12/ SG Patient/ General population US (adjusted)/ Australia
Pataky et al. [26] Canada Healthcare based on included costs SG 2 different patient groups Canada
Roth et al. [28] US US payer perspective SG Patient US
  1. HUI Health utility index, QoL quality of life, SG standard gamble, TTO Time trade off. aThe exact source of the value for advanced disease is unclear, it is likely to reflect a synthesis of EQ-5D and 15D.b assumed SF measures converted to SF-6D